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Abstract
It is common that in multiarm randomized trials, the outcome of interest is “truncated by death,”
meaning that it is only observed or well defined conditioning on an intermediate outcome. In this case,
in addition to pairwise contrasts, the joint inference for all treatment arms is also of interest. Under
a monotonicity assumption we present methods for both pairwise and joint causal analyses of ordinal
treatments and binary outcomes in presence of truncation by death. We illustrate via examples the
appropriateness of our assumptions in different scientific contexts.
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1 Introduction
In multiarm randomized trials, researchers are often interested in analyzing treatment effects on an outcome
that is measured or well defined only when an intermediate outcome takes certain values (Robins, 1986;
Rubin, 2000, 2006; Egleston et al., 2007; Chiba and VanderWeele, 2011; Ding et al., 2011). For example,
consider a multiarm randomized HIV vaccine trial. Scientists might be interested in evaluating vaccine
effects on HIV viral load as it correlates with infectiousness and disease progression (Hudgens et al., 2003;
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Gilbert et al., 2003). However, HIV viral load is typically measured only for infected individuals. Two
problems occur in this case: in general, there are many potential comparisons that can be made between
different vaccination groups among infected subjects; moreover, these comparisons are subject to selection
bias as the vaccine may affect susceptibility to HIV infection. In the simple case of a two-arm trial, to deal
with the selection bias problem, several authors have proposed to consider the vaccine effects on viral load
among the always-infected stratum, the subpopulation who would become infected regardless of whether
they are vaccinated or not (e.g., Hudgens et al., 2003; Gilbert et al., 2003). However, there has not been
much work on analyzing this type of trial with more than two arms.
By convention, the intermediate outcome is called “survival,” and we say the final outcome is “truncated
by death” if it is only observed and/or well-defined for “survivors.” Thus in the HIV vaccine example above,
the always-infected stratum is referred to as the “always-survivor” stratum. The causal contrast among the
always-infected subjects is hence called the (always-)survivor average causal effect (SACE) (Rubin, 2000;
Robins, 1986, §12.2).
In general, even in a two-arm trial, the SACE is not identifiable without strong untestable assumptions.
As a result, there are no consistent tests for detecting non-null vaccine effects in the always-infected stratum.
Instead, under some reasonable assumptions, Hudgens et al. (2003) tested the null hypothesis presuming
the maximal degree of selection bias. Their approach is related to estimation of bounds on SACE, which
has been extensively studied in literature. For example, Zhang and Rubin (2003) developed bounds on
SACE under various assumptions including the monotonicity assumption and the stochastic dominance
assumption. Imai (2008) provided an alternative proof that the bounds of Zhang and Rubin (2003) are
sharp by formulating the truncation-by-death problem as a “contaminated data” problem. These testing and
estimation methods are appealing in practice as they don’t rely on strong identifiability assumptions.
However, so far as we are aware, there has not been much discussion on testing and estimation of
SACEs in a multiarm trial, which is fairly common in medical practice (Schulz and Grimes, 2005). Prior to
our work, Lee et al. (2010) considered a sensitivity analysis approach to identify all SACEs in a three-arm
trial. Their identification results rely on a strong parametric assumption and several sensitivity parameters.
In this article, we instead propose a framework to systematically analyse SACEs in a general multiarm trial
without strong identification assumptions. To the best of our knowledge, our method is also the first that is
readily applicable to randomized trials with more than three treatment arms under truncation by death.
The testing and estimation of SACEs in a multiarm trial are more challenging compared to two-arm
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trials. Firstly, in general there are many different SACEs that are well-defined. As we show later in Section
2.2, consideration of all SACEs (as in Lee et al. (2010)) can lead to paradoxical non-transitive conclusions.
Hence we instead restrict our attention to comparisons within the “finest” (principal) strata, thereby avoiding
this difficulty. Secondly, one needs to distinguish between an overall analysis of treatment effects and
a separate analysis of each individual contrast. In the simple setting without truncation by death, it is
widely known that compared to all pairwise comparisons with correction for multiple comparisons, an
overall analysis such as an ANOVA test often provides more power for testing the overall treatment effect
in a multiarm trial. When truncation by death is present, because of the non-identifiability of SACEs, this
advantage becomes more fundamental as non-identifiability remains even when the sample size goes to
infinity. In contrast to Lee et al. (2010), we distinguish between simultaneous versus marginal inference
for SACEs, and argue that they should be used to answer different questions. In particular, we show that
compared to marginal inference procedures, our proposed simultaneous inference procedures provide more
power for testing the overall treatment effect and the advantage remains even with an infinite sample size.
Thirdly, the simultaneous inference problem is unique to a multiarm trial. Again, since SACEs are not
identifiable, traditional statistical inference tools for multiarm trials without truncation by death are not
directly applicable to our setting. Instead, we develop novel simultaneous inference procedures to test an
overall treatment effect, and show that they have desirable asymptotic properties. We also generalize the
marginal inference procedures for a two-arm trial to get sharp bounds on SACEs for a general multiarm
trial. To focus on addressing these challenges, in this paper, we restrict our attention to trials with ordinal
treatment groups and binary outcomes.
The rest of this paper is organized as follows. In Section 2, we introduce our notations, assumptions
and define our causal estimands. We also address the transitivity issue and identify three specific testing and
estimation questions that may arise in a general multiarm trial with truncation by death. We then propose
three novel procedures that answer these questions in Sections 3, 4 and 5. In Section 3, we discuss the unique
challenges for hypothesis testing with non-identifiable parameters, and develop a novel step-down testing
procedure to test the overall treatment effect in this situation. In Section 4, we develop a linear programming
algorithm to test an overall clinically relevant treatment effect. In Section 5, we derive the sharp marginal
bounds for each causal contrast of interest. In Section 6, we illustrate the proposed procedure with real data
analyses. Results from simulation studies can be found in the the Supplementary Materials. We end with a
discussion in Section 7.
3
The programs that were used to analyse the data can be obtained from
http://wileyonlinelibrary.com/journal/rss-datasets.
2 Framework
2.1 Data structure and assumptions
Consider a multiarm trial with a control arm and multiple arms of active treatment. Let Z be an ordinal
treatment variable, where Z = 0 corresponds to the control treatment, and Z ∈ {1, . . . ,m} corresponds to
different arms of active treatment. In what follows, we use the terminology “treatment arms” and “treatment
levels” interchangeably. We assume that each subject has m+ 1 dichotomous potential outcomes Y (z), z =
0, . . . ,m, where Y (z) is defined as the outcome that would have been observed if the subject had been
assigned to treatment arm z. Similarly, we define S(z) as the potential survival status under treatment
assignment z. We assume Y (z) is well-defined only if S(z) = 1. In other words, the outcome of interest
is well-defined only for subjects who survive to the follow-up visit. We also assume that the observed data
(Zi, Si, Yi; i = 1, . . . , N) are independently drawn from an infinite super-population.
Let G = (S(0), . . . , S(m)) denotes the basic principal stratum (Frangakis and Rubin, 2002). If we let
the letter L denote S(z) = 1 (meaning “live”) and the letterD denote S(z) = 0 (meaning “die”), thenG can
be rewritten as a string consisting of the letters “L” and “D.” For example, in a three-arm trial, Gi = DLL
indicates that subject i would die under control, but would survive under active treatment 1 or 2.
We make the following assumptions.
Assumption 1: Stable unit treatment value assumption (SUTVA (Rubin, 1980)): there is no interference
between units, and there is only one version of treatment.
Under the SUTVA, the observed outcome equals the potential outcome under the observed treatment
arm, namely Y = Y (Z) and S = S(Z).
Assumption 2: Random treatment assignment: Z |= (S(0), . . . , S(m), Y (0), . . . , Y (m)).
Assumption 3: Monotonicity: Si(z1) ≥ Si(z2), i = 1, . . . , N, z1 ≥ z2.
The monotonicity assumption is sometimes plausible in social science studies if the treatment options
can be reasonably ordered. For example, in randomized experiments evaluating the effect of incentives on
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survey response quality, it is intuitive that higher level of incentives would not hurt survey response rates.
This assumption tends to be more controversial in medical studies where S represents survival, in which
there are often trade-offs between treatment benefits and side effects.
The only possible strata under the monotonicity assumption are strata of the form D · · ·DL · · ·L. To
compress notation, we denote all possible principal strata as (DkLm+1−k; k = 0, . . . ,m+ 1), where mem-
bers of principal stratum DkLm+1−k would die if assigned to the first k treatment arms but would survive
if assigned to the remaining m+ 1− k treatment arms.
2.2 Causal estimands and questions
For randomized trials with two treatment arms, it is common to estimate the average causal effect in the
LL stratum (Kalbfleisch and Prentice, 1980; Robins, 1986; Rubin, 2000), the only subgroup for which
both of the potential outcomes are well-defined: SACE = E[Y (1) − Y (0) | G = LL]. In a general
multiarm trial, researchers may be interested in comparisons of potential outcomes within the same basic
principal stratum. For example, in the case where we have three levels of treatment: 0, 1, 2, the target
estimands are E[Y (2) − Y (1) | G = LLL], E[Y (1) − Y (0) | G = LLL], E[Y (2) − Y (0) | G = LLL]
and E[Y (2) − Y (1) | G = DLL]. These contrasts are causally meaningful as the memberships of basic
principal strata are defined at baseline.
To define the causal estimands for a general multiarm trial, we first introduce some notation. Let µzg ≡
E[Y (z) | G = g] denote the mean potential outcome under treatment assignment z in basic principal
stratum g. Also, letM(g) denote the minimal treatment level under which members of principal stratum
g can survive. In other words, for members of principal stratum g, S(z) = 1 if and only if z ≥ M(g).
Consequently, µzg is well-defined if and only if z ≥ M(g). Under the monotonicity assumption, all basic
principal strata take the form g = DkLm+1−k. By definition, M(DkLm+1−k) = k. Also let Ωk = {g :
M(g) ≤ k} denote the collection of basic principal strata whose members would survive if assigned to
treatment arm k. The pairwise causal estimands in a multiarm trial then take the form
∆(z1, z2; g) ≡ µz1g − µz2g , where g ∈ Ωm−1, z1 > z2 ≥M(g). (1)
For notational simplicity, in this article, when we write the notation µzg and ∆(z1, z2; g), we always assume
that it is well-defined. We also note that the parameters involved in defining the causal contrasts ∆(z1, z2; g)
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are contained in the parameter vector µm−1 ≡ (µzg; g ∈ Ωm−1, z ≥M(g)).
Other meaningful causal contrasts are made within coarsened principal strata, defined as groups that
combine several basic principal strata (Cheng and Small, 2006). For example, in the case of a three-arm
trial, the contrast E[Y (2) − Y (1) | G ∈ {LLL,DLL}] is also causally meaningful as memberships of
the coarsened principal strata {LLL,DLL} are also defined at baseline. Some previous researchers hence
consider coarsened principal strata causal effects together with basic principal strata causal effects (e.g. Lee
et al., 2010). However, as Robins (1986) noted, if one were to compare E[Y (2) − Y (0) | G = LLL],
E[Y (1) − Y (0) | G = LLL] and E[Y (2) − Y (1) | G ∈ {LLL,DLL}] simultaneously, it is possible that
the last two comparisons are both positive while the first one is negative. This lack of transitivity limits the
interpretability of causal effects defined within coarsened principal strata. In contrast, transitivity holds if
limited to basic principal strata (e.g., LLL). Hence in this article, we are primarily interested in comparisons
between potential outcomes in the same basic principal stratum.
On the other hand, as Robins et al. (2007) noted, the size of each basic principal stratum is likely to be
very small and consequently, each comparison in (1) only applies to a small portion of the population. Hence
for randomized trials with more than three treatment arms, we may have limited power to test treatment
effects for each basic principal stratum. What is more, we run into the problem of multiple comparisons as
there are multiple treatment arms and multiple basic principal strata.
Therefore, we first consider testing the global null hypothesis that the treatment is not effective in any of
the basic principal strata (for which some treatment comparison is well-defined). This question is scientifi-
cally relevant. For example, in a HIV vaccine trial, testing the global null addresses whether there exists a
mechanism through which the vaccine alters viral load in infected individuals (Shepherd et al., 2006). Sec-
ondly, clinicians may also be interested in whether the overall treatment effect is clinically meaningful so
that the active treatment is promising in clinical practice. For this purpose, an overall treatment effect may be
declared only if it is greater than the clinical margin of relevance specified by clinicians. Finally, besides an
overall treatment effect, scientists and clinicians may also be interested in isolating the non-zero/non-trivial
causal contrasts. In summary, the following questions are of interest with a multiarm trial:
1. Is there evidence of the existence of non-zero average treatment effects for at least one basic principal
stratum between at least two treatment arms?
2. Are there clinically relevant average treatment effects for at least one basic principal stratum between
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at least two treatment arms?
3. Can we find the specific principal strata and treatment arms that correspond to the overall non-
zero/clinically relevant treatment effect, if such exists?
We address these questions in Section 3, 4 and 5 respectively. Existing causal analysis literature in multiarm
trials with non-identifiable causal estimands (Cheng and Small, 2006; Long et al., 2010; Lee et al., 2010)
focuses on answering the third question. However, as we explain later in Remark 3, one may be able to
answer the first two questions even if there is not enough information to answer the third. Hence it is
important to consider all three questions.
3 Testing treatment effects in a multiarm trial
To find out if there is an overall non-zero treatment effect, it is desirable to consider the following testing
problem:
H0 : ∆(z1, z2; g) = 0, ∀z1, z2, g vs Ha : ∃z1, z2, g s.t. ∆(z1, z2; g) 6= 0, (2)
where ∀ means “for all,” ∃ means “there exists” and s.t. means “such that.” The testing problem (2) is
fundamentally different from (and more difficult than) a standard testing problem, in which one assumes
if the observed data distribution was known, one would also know whether or not the hypothesis is true
(Lehmann and Romano, 2006). The main difficulty here is that H0 is a statement about non-identifiable
parameter vector µm−1. In other words, even if the population probabilities P (S = 1 | Z = z) and
P (Y = 1 | S = 1, Z = z) were known, we could only ascertain that µm−1 resides in a region, and
therefore may not know whetherH0 is true or not.
Nevertheless, µm−1 is “partially identifiable” in the sense that the observed data distribution can narrow
down the range in which µm−1 can possibly lie (Cheng and Small, 2006). For example, in a three-arm trial,
the domain of µ2 is [0, 1]
6. However, if the observed data distribution was known, the feasible region of µ2
would be a subspace in [0, 1]6 subject to the following constraints:
P (Y = 1 | Z = 0, S = 1) = µ0LLL,
P (Y = 1 | Z = 1, S = 1) = p1LLLµ1LLL + p1DLLµ1DLL,
P (Y = 1 | Z = 2, S = 1) = p2LLLµ2LLL + p2DLLµ2DLL + p2DDLµ2DDL, (3)
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where pzg ≡ P (G = g | Z = z, S = 1) is identifiable under Assumptions 2 and 3 (see Lemma 1 in the
Supplementary Materials). Figure 1 provides a graphical representation of the functional relations described
in (3).
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Figure 1: A graph representing the functional dependencies in the causal analysis of a three-arm random-
ized trial with truncation by death. Rectangular nodes represent observed variables; oval nodes represent
unknown parameters, with different shadings corresponding to different principal strata. Under the mono-
tonicity assumption, pzg can be identified from observed quantities P (S = 1 | Z = z).
For a general multiarm trial, if the parameter space defined by H0 has no intersection with the feasible
region of µm−1, one would know that H0 is not true. In general, we introduce the following notions for
hypothesis testing with non-identifiable parameters.
Definition 1: We define a hypothesis relating to a parameter to be compatible with an observed data distri-
bution if the parameter space defined by the hypothesis has a non-empty intersection with the feasible region
of the parameter under the observed data distribution.
In particular, if a parameter is completely unidentifiable such that the observed data distribution imposes
no constraints on the parameter, then all hypotheses relating to that parameter are compatible with the
observed data distribution. On the other hand, if a parameter is identifiable so that its feasible region under
the observed data distribution is always a single point set, then all compatible hypotheses are true.
In general, however, not all compatible hypotheses are true. Nevertheless, owing to lack of identifiability,
a true hypothesis may not be distinguishable from data with an untrue yet compatible hypothesis. This leads
to the following notion of sharpness.
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Definition 2: We define a test to be sharp for testing a null hypothesis if when the null is not compatible
with the observed data distribution (and is hence untrue), the power of the test tends to 1 when the sample
size goes to infinity.
Intuitively, similar to consistent tests, sharp tests are those that maximize power asymptotically. The
difference is that as the sample size goes to infinity, with probability tending to 1, sharp tests reject any
hypotheses that are incompatible with the observed data distribution, whereas consistent tests reject any
hypotheses they are untrue. In small sample settings, however, the conclusions that one would draw from
a sharp test are similar to those from a consistent test. If a hypothesis is rejected, one would conclude that
it is untrue (at a certain significance level); if otherwise, no claims about the correctness of the hypothesis
would be made. We also note that for a standard hypothesis testing problem as described in Lehmann
and Romano (2006), sharp tests are the same as consistent tests. When the null hypothesis concerns non-
identifiable parameters, however, there are in general no consistent tests. Instead, sharpness plays the role
of consistency in a standard hypothesis testing problem.
The notion of sharp tests is similar in spirit to the notion of sharp bounds, defined as the tightest possible
bound given the observed data distribution (e.g., Imai, 2008). This notion has also been used implicitly in
previous works. For example, Hudgens et al. (2003)’s test for SACE in a two-arm trial is sharp.
Below in Section 3.1, we develop a sharp test for problem (2) under the presumption that the observed
data distribution is known. In other words, we assume the sample size is infinite such that there is no
stochastic variation in the observed data. In Section 3.2 we incorporate sampling uncertainty to our proposed
test using a Bayesian method.
3.1 A step-down procedure for testing the global nullH0
To fix ideas, we first consider the problem of a three-arm trial, for whichH0 holds if and only if
µ0LLL = µ
1
LLL = µ
2
LLL (4)
and
µ1DLL = µ
2
DLL. (5)
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We hence propose a two-step procedure. Firstly we test hypothesis (4). If (4) is compatible with the observed
data distribution, we then test if (5) is compatible with the observed data distribution conditioning on (4).
Specifically, one can see from Figure 1 that µ0LLL is identifiable from the observed data and suppose
the feasible regions of µ1LLL and µ
2
LLL are B01 and B02, respectively. If µ
0
LLL is not contained in the
intersection of B01 and B02, then (4) and hence H0 are not compatible with the observed data distribution.
If otherwise, so that (4) is compatible with the observed data distribution, we then test hypothesis (5) under
the assumption that hypothesis (4) holds. Note that, under hypothesis (4), µ1LLL and µ
2
LLL are identifiable.
Consequently, µ1DLL is identifiable. Suppose the feasible region of µ
2
DLL under the constraint (4) is B12.
If µ1DLL is not contained in B12, we conclude that (5) is not compatible with the observed data distribution
under the constraint (4) and hence reject H0. If otherwise, we conclude that H0 is compatible with the
observed data distribution.
Algorithm 1 generalizes the procedure described above to general multiarm trials. Theorem 1 states the
asymptotic optimality of Algorithm 1. The proof is provided in the Supplementary Materials.
Algorithm 1 A step-down algorithm for testing the global null hypothesisH0
1. Set k = 0
2. For z = k, . . . ,m
obtain the feasible region (under the maintained assumptions)Bkz for µzDkLm+1−k (see Theorem
2)
3. If ∩
z=k,...,m
Bkz = ∅
rejectH0; report k; stop
else
set µkDkLm+1−k = · · · = µmDkLm+1−k (6)
4. If k = m
fail to rejectH0 and stop
else
set k = k + 1 and go to Step 2
Theorem 1: The test given by Algorithm 1 is sharp for testing H0. In other words, it is asymptotically
optimal for testingH0 as it maximizes power given the observed data distribution.
To derive the feasible regions (Bkz; k = 0, . . . ,m, z = k, . . . ,m) in Algorithm 1, we introduce notation
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building on Horowitz and Manski (1995). Let QzG(·) denote the distribution (function) of outcome Y among
members of subgroup G who receive treatment z, and δx(·) be a degenerate distribution function localized
at x. As Y is binary, QzG(·) is a Bernoulli distribution with mean mG(z): QzG(·) = (1 − mG(z))δ0(·) +
mG(z)δ1(·). To compress notation, we write QzG(·) as QzG . Also let Lλ(Q) and Uλ(Q) be functionals that
map a distribution function Q to the corresponding distributions truncated at the lower λ quantile and upper
λ quantile, respectively. Theorem 2 gives the formula for feasible region Blz .
Theorem 2: Suppose that the observed data distribution is known and (6) holds for all k < l. Let
g = DlLm+1−l and g = ∪
g¯∈Ωz\Ωl−1
g¯ be the coarsened principal stratum whose members would survive
if assigned to treatment z but would die if assigned to treatment l − 1. The feasible region of µzg is
Blz =
[∫
ydLωzg (Q
z
g),
∫
ydUωzg (Q
z
g)
]
, (7)
where ωzg ≡ P [G = g | G ∈ Ωz \ Ωl−1] = pzg
/( ∑
g∈Ωz\Ωl−1
pzg
)
and Qzg is a Bernoulli distribution with
mean
mg(z) =
m(z)− ∑
g∈Ωl−1
pzgµ
z
g
/1− ∑
g∈Ωl−1
pzg
 ,
in which m(z) ≡ P [Y = 1 | Z = z, S = 1].
Intuitively, the bounds of Blz are obtained by assigning the smallest/largest ωzg portion of observed
outcome values in distribution Qzg to principal stratum g. The proof is in the Supplementary Materials.
Remark 1: Algorithm 1 is a “step-down” procedure in the sense that the hypothesisH0 is decomposed into
a series of hypotheses where the first hypothesis concerns the first stratum Lm+1, the second hypothesis
concerns the second stratum DLm conditioning on the first hypothesis, and so on.
3.2 Bayesian procedures
We have so far developed a sharp test for problem (2). In practice, however, sampling uncertainty must be
taken into account when making statistical inference. Here we introduce a Bayesian procedure to estimate
the posterior probability thatH0 is not compatible with the observed data distribution. The Bayesian method
produces multiple samples of the posterior distribution, thereby reflecting randomness in observed data.
Let p(s, y | z) = P (S = s, Y = y | Z = z) and p(·, · | z) = (p(1, 1 | z), p(1, 0 | z), p(0, ↑| z)), where
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↑ indicates that Y is undefined when S = 0. Define p = (p(·, · | 0), . . . , p(·, · | m)). Under independent
Dirichlet priors over the observed distributions p(·, · | z), z = 0, . . . ,m, it is easy to sample from the
posterior distribution via conjugacy. We propose to use Algorithm 2 to calculate the posterior probability
thatH0 is not compatible with the observed data distribution.
Algorithm 2 A Bayesian procedure for testingH0
1. Place an independent Dirichlet prior Dir(α3z+1, α3z+2, α3z+3) on p(·, · | z), z = 0, . . . ,m.
2. Simulate samples p(1), · · · ,p(M) from the posterior distributions, which are independent Dirichlet
distributions
Dir(α3z+1 + n3z+1, α3z+2 + n3z+2, α3z+3 + n3z+3), z = 0, . . . ,m,
where n3z+1 =
N∑
i=1
I(Si = 1, Yi = 1, Zi = z), n3z+2 =
N∑
i=1
I(Si = 1, Yi = 0, Zi = z), n3z+3 =
N∑
i=1
I(Si = 0, Zi = z).
3. Run Algorithm 1 with each of the posterior samples satisfying the following inequalities:
P (S = 1 | Z = m) ≥ · · · ≥ P (S = 1 | Z = 1) ≥ P (S = 1 | Z = 0) (8)
Note (8) characterizes the set of observed data distributions arising from the potential outcome model
defined by Assumptions 1 - 3.
4. Report the proportion of posterior samples with whichH0 is rejected.
Remark 2: The step-down procedure in Algorithm 1 has a similar structure to the sequential tests for nested
hypotheses discussed by Rosenbaum (2008). His procedure has attractive Frequentist properties since it
controls the type I error rate without resorting to multiplicity adjustment. However, with his methods one
proceeds to the next step if the current hypothesis is rejected whereas in our proposal, one proceeds if the
current hypothesis is not rejected. Moreover, in his context, the parameters of interest are identifiable. Hence
Rosenbaum’s results are not directly applicable to our case.
4 Testing clinically relevant treatment effects in a multiarm trial
If a non-zero treatment effect is found using Algorithm 2, a natural question arises as to whether the treat-
ment effect is clinically meaningful. Suppose the margin of clinical relevance is ∆0 such that a treatment
effect smaller than this would not matter in practice, and also suppose that the treamtent effect is clinically
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meaningful only if a higher treatment level corresponds to a higher mean potential outcome. It is desirable
to consider the following testing problem:
H0,c : ∆(z1, z2; g) ≤ ∆0,∀g, z1 ≥ z2 vs Ha,c : ∃g, z1 ≥ z2 s.t. ∆(z1, z2; g) > ∆0, (9)
where the letter “c” in H0,c is short for “clinical relevance.” Similar to (2), (9) is a testing problem on
non-identifiable parameters. However, as the null parameter space is a non-degenerate region in the domain
of µm−1, the step-down procedure developed in Section 3 is not applicable. Instead, we define ∆max to be
the largest ∆(z1, z2; g) that appears in H0,c: ∆max = max
g,z1≥z2
∆(z1, z2; g). (9) can then be rewritten in an
equivalent form using ∆max: H0,c : ∆max ≤ ∆0 vs Hα,c : ∆max > ∆0. The following lemma says
the testing problem (9) can be translated into the identification problem on ∆max.
Lemma 1: Suppose the sharp (large sample) lower bound for ∆max is ∆max,slb. A sharp test would reject
H0,c if and only if ∆max,slb > ∆0.
As ∆max is a function of µm−1, in general, identifying ∆max,slb involves minimizing ∆max subject to
the constraints on µm−1 imposed by the observed data distribution. Theorem 3 below says that the feasible
region of µm−1 is a convex polytope, defined as an intersection of finitely many half spaces. Consequently,
this optimization problem can be translated into a linear programming problem and efficiently solved with
off-the-shelf software. See Algorithm 1 in the Supplementary Materials for more details.
Theorem 3: Given the observed data distribution, the feasible region ofµm−1 is a subspace in [0, 1]
dim(µm−1)
subject to the following constraints:
∑
g∈Ωz
pzgµ
z
g = m(z), z = 0, . . . ,m− 1;
max (0,m(z)− pzDmL) ≤
∑
g∈Ωm−1
pzgµ
z
g ≤ min (1− pzDmL,m(z)) , z = m,
where pzg is identifiable from data under Assumptions 2 and 3 (see Lemma 1 in the Supplementary Materi-
als). In particular, the feasible region of µm−1 is a convex polytope.
To incorporate statistical uncertainty, one can use Bayesian analysis methods to derive a credible interval
for ∆max,slb. Specifically, one runs Steps 1-4 in Algorithm 2 to get multiple posterior samples that satisfy
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the constraint (8), and then produces a percentile based credible interval for ∆max,slb based on the posterior
samples. One may also estimate the posterior probability of rejecting H0,c for any given positive value ∆0
with these posterior sample draws.
5 Marginal credible intervals for a given contrast
If a clinically non-trivial treatment effect is found, then it is desirable to identify the principal strata and
treatment arms that correspond to this treatment effect. In this case, the marginal feasible regions and
associated credible intervals for ∆(z1, z2; g) are of interest.
If the observed data distribution was known, then the feasible region for ∆(z1, z2; g) can be obtained
from the feasible regions for µz1g and µ
z2
g . Specifically, we have the following theorem.
Theorem 4: Suppose the observed data distribution is known, and BM(g),z1 and BM(g),z2 are feasible
regions for µz1g and µ
z2
g , respectively. Then we have the following results.
1. For z = z1, z2, BM(g),z =
[∫
ydLpzg(Q
z),
∫
ydUpzg(Q
z)
]
.
2. The feasible region of ∆(z1, z2; g) is
[∫
ydLpz1g (Q
z1)− ∫ ydUpz2g (Qz2), ∫ ydUpz1g (Qz1)− ∫ ydLpz2g (Qz2)] .
In practice, credible intervals for ∆(z1, z2; g) can be constructed from posterior sample draws p(1), . . . ,p(M).
These posterior draws may also be used to estimate the posterior probability of rejecting the null hypothesis
H0,m : ∆(z1, z2; g) ≤ ∆0, where the letter “m” inH0,m is short for “marginal.”
Remark 3: We remark that even if the observed data provide evidence for the existence of non-zero/non-
trivial treatment effects, it is possible that they do not contain information on the specific principal strata
and treatment arms that correspond to these treatment effects. Moreover, unlike the case for multiarm trials
without truncation by death, this can happen even with an infinite sample size.
We illustrate our point with the following numerical example. Consider a three-arm trial such that
piLLL = piDLL = piDDL = 0.3, piDDD = 0.1,m(0) = 0.3,m(1) = 0,m(2) = 0.5, where pig ≡ P (G = g).
In this case, µ0LLL = 0.3 and µ
1
LLL = µ
1
DLL = 0. It follows that ∆max = max(0, µ
2
LLL − µ1LLL, µ2DLL −
µ1DLL). We assume that the sample size is infinite so that we know the observed data distribution. Figure
2 shows the joint feasible region of (µ2LLL − µ1LLL, µ2DLL − µ1DLL) (the green shaded area). Suppose
that the margin of clinical relevance ∆0 is 0.1, then the acceptance region for null hypothesis H0,c is the
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lower left area of the blue contour line. As there is no intersection between the feasible region of (µ2LLL −
µ1LLL, µ
2
DLL − µ1DLL) and the acceptance region for H0,c, one may conclude that H0,c should be rejected.
Alternatively, one can see from the contour lines of ∆max that the sharp lower bound for ∆max is 0.25. As
∆0 is smaller than ∆max,slb, one also rejectsH0,c.
µLLL
2
− µLLL
1
µDLL
2
− µDLL
1
0.1
0.25
0.4
−0.5 0.0 0.5 1.0
−
0.
5
0.
0
0.
5
1.
0
Figure 2: Feasible region of (µ2LLL − µ1LLL, µ2DLL − µ1DLL) (green shaded area). The colored lines are
contour lines of ∆max. The sharp lower bound of ∆max is obtained at the red point.
However, by projecting the joint feasible region of (µ2LLL−µ1LLL, µ2DLL−µ1DLL) onto individual axises,
one concludes that the marginal feasible regions for µ2LLL−µ1LLL and µ2DLL−µ1DLL are both [0, 1]. As both
of the marginal feasible regions contain values that are smaller than ∆0, the data contain no information on
the specific contrast that corresponds to the overall treatment effect.
6 Data Illustrations
6.1 Application to the HIV Vaccine Trials Network 503 study
The HIV Vaccine Trials Network (HVTN) 503 HIV vaccine study was a randomized, double-blinded,
placebo-controlled Phase IIb test-of-concept clinical trial to investigate the efficacy and safety of an ex-
perimental HIV vaccine. The same vaccine was also evaluated in a different population in an earlier HVTN
502/Step trial. Starting January, 2007, the HVTN 503 study enrolled 800 HIV negative subjects and ran-
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domized them to receive three doses of either the study vaccine or a placebo. The ratio of vaccine to placebo
assignment was 1:1. Enrollment and vaccinations were halted in September 2007, but follow-up continued,
after the HVTN 502/Step trial met its prespecified non-efficacy criteria. Details of this study can be found
in Gray et al. (2011, 2014).
In our analysis, we compared CD4 counts among participants within the same principal stratum defined
by their full potential infection statuses. Due to the early stopping of vaccinations of the trial, a majority
of participants in the HVTN 503 trial were not fully immunized. When enrollment was stopped, 400 par-
ticipants in the HVTN 503 trial were assigned to the experimental vaccine group. Of them, 112 received
one injection, 259 received two injections, and only 29 received all three injections. Hence we considered
the dosage of experimental vaccine as the treatment arm Z, where Z = 0 for all subjects in the control
group. As the trial was stopped administratively, and the time a participant entered this trial was unlikely to
affect the potential outcomes of interest (CD4 count), it is reasonable to assume that the treatment arms were
randomized. Furthermore, since there were only 3.6% of participants who received all three experimental
vaccines, we code Z = 2 for all participants who receive two or more experimental vaccine injections.
A total of 100 subjects were infected during this trial. We defined each subject’s “median CD4 count”
(the outcome of interest) as their median CD4 count measured between their confirmatory HIV testing visit
and the end of follow-up or start of antiretroviral treatments. We also dichotomized CD4 count at 350
cells/mm3 and 200 cells/mm3 as they have been used in previous United States Department of Health and
Human Services (DHHS) guidelines for initiating antiretroviral treatment. Note that the outcome measure
is only measured for infected subjects. As 87.5% of the study subjects were uninfected, an intent-to-treat
analysis with imputation for missing CD4 count values is likely to have very low power for detecting any
treatment effects (Gilbert et al., 2003). Hence SACEs are of interest for analyzing this trial.
Table 2 in the Supplementary Materials summarizes the observed data for the study participants. There
were 7 infected participants who had no CD4 count measurements after their confirmatory HIV testing visit.
We made the missing completely at random (MCAR) assumption and left them out of our analysis below. In
treatment arm 0, 1, 2, the mean number of CD4 counts available were 5.69, 5.94 and 5.57, respectively; the
mean length of time from the confirmatory HIV testing visit to the first CD4 count measure were 26 days,
25 days and 32 days, respectively, and the mean time spacing between CD4 count measurements were 127
days, 146 days and 134 days, respectively.
Presumably there was little interaction among HVTN 503 subjects so that the SUTVA was plausible.
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Subsequent analyses of the HVTN 502 and HVTN 503 data suggested that although not possible to directly
cause HIV infections itself, the investigational vaccine may increase susceptibility to HIV infection for re-
cipients (Gray et al., 2011, 2014). Given the negative results on the primary efficacy endpoints, members of
the HVTN 503 Protocol Team whom we consulted agreed that it is reasonable to make the reverse mono-
tonicity assumption such that experimental vaccine did not help prevent HIV infection for any participant
in the study population. The empirical infection rates in the Z = 0, 1, 2 arms were 9.25%, 16.07% and
15.63%, respectively. Thus, the reverse monotonicity assumption seemed acceptable, and we proceeded
with our analysis under this assumption.
Table 1 summarizes the analysis results. The simultaneous testing method estimates the posterior prob-
ability of existence of an overall non-zero treatment effect, while the marginal testing method estimates
the posterior probability that an overall non-zero treatment effect can be claimed along with the specific
treatment arms and principal strata that correspond to this treatment effect. These posterior probabilities
were high, suggesting evidence of a non-zero treatment effect on median CD4 falling below 350 or 200
cells/mm3. The 95% credible intervals for lower bound on ∆max provide information on the magnitude
of vaccine effects. For example, results in Tables 1 show that there exists at least one basic principal stra-
tum and treatment comparison for which the vaccine reduces the probability of median CD4 count ≤ 200
cells/mm3 by at least 0.026, but we were not able to ascertain the specific basic principal stratum and treat-
ment comparison that corresponds to this effect. The reason for this is two fold. Firstly, because of the
non-identifiability of the SACEs, if the effect size is too small, one may fail to identify the specific causal
contrast that corresponds to a clinically relevant treatment effect even with an infinite sample size. Secondly,
our proposed methods may deliver more conclusive results if the sample size is large enough. For example,
if the sample size was 3000 (which was the estimated sample size in the HVTN 503 trial protocol) and the
observed frequencies P (S = 1 | Z = z) and P (Y = 1 | Z = z, S = 1) had remained the same, then the
95% credible interval for the contrast µ2LLL−µ0LLL would have been [0.057, 0.186], which would imply that
compared to the placebo, receiving two or more injections of the experimental vaccine is clinically effective
for reducing the possibility of very low CD4 cell counts (200 cells/mm3 or less) among subjects who would
get infected regardless of which treatment arm they were assigned to.
We conclude this part with several caveats. First, the median CD4 count is a non-traditional endpoint
for HIV vaccine efficacy trials, and it may not be completely comparable between treatment groups because
of differences in the number and timing of CD4 measurements. Second, we have dichotomized CD4 count
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Table 1: Posterior probabilities of finding a non-zero overall treatment and posterior credible intervals for
lower bounds on ∆max (the maximal treatment effect over all principal strata and treatment comparisons)
for the HVTN 503 trial
Methods Posterior probability of a 95% credible interval for
non-zero treatment effect lower bound on ∆max
Outcome:median CD4 > 350
Simultaneous 0.882 [0.000, 0.346]
Marginal 0.651 [0.000, 0.341]
Outcome:median CD4 > 200
Simultaneous 0.996 [0.026, 0.260]
Marginal 0.973 [6× 10−4, 0.245]
in our analysis, which results in loss of information. Third, we have made the MCAR assumption for the
missing values in CD4 count measures, which is hard to verify for this data set. Fourth, as pointed out by
some authors (e.g. Pearl, 2011), under the principal stratification framework we have taken here, the vaccine
effect estimates are only relevant for the subgroup of subjects who would get infected under at least two
dosage levels, which constitutes only a small fraction of the population. Finally, a reduction of 0.026 in the
probability of median CD4 counts ≤ 200 cells/mm3 may not be considered clinically important given the
earlier finding that the vaccine increased HIV acquisition in the study population.
6.2 Application to survey incentive trials
Faced with declining voluntary participation rates, there is now a consensus that incentives are effective
for motivating response to surveys (Singer and Kulka, 2002; Singer and Ye, 2013). There is, however,
controversy on how incentives affect the quality of data collected. Social exchange theory suggests that
by establishing an explicit exchange relationship, incentives not only encourage participation in surveys,
but also encourage respondents to provide more accurate and complete information (Davern et al., 2003).
However, current experimental studies have mixed findings on this hypothesis (Singer and Kulka, 2002;
Singer and Ye, 2013).
These experimental studies directly compare response quality in different incentive groups without ac-
counting for the problem of truncation by response. Here the treatments Z are the levels of incentive, the
intermediate outcomes S are the responses to the surveys, and the final outcomes Y are measures of survey
quality. Although some researchers realize that people persuaded to participate through the use of incentives
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will have less internal motivation for filling out the survey thoroughly (e.g. Davern et al., 2003), few, if any,
separate this group of people in their analyses from those who would participate in the survey regardless of
incentive levels, rendering their results subject to selection bias. Furthermore, arguably the response quality
is undefined for survey non-respondents. Thus as argued by Rubin (2006) and others, the naive comparison
is not causal as it compares different groups of people at baseline. Instead, for two-arm trials, the SACE is
of interest as the subgroup whose members would respond regardless of the level of incentive is the only
group for which both of the potential outcomes are well-defined. This holds similarly for multiarm trials.
Moreover, it is very common that such randomized experiments have multiple incentive groups (Singer and
Kulka, 2002; Singer and Ye, 2013). Hence the methodology introduced in this paper, and more generally,
identification and estimation methods for SACEs in multiarm trials are especially relevant.
For example, Curtin et al. (2007) used data from the Survey of Consumer Attitudes (SCA) conducted by
the University of Michigan Survey Research Center to investigate whether efforts to increase the response
rate jeopardize response quality. Their analysis was based on a random digit dial telephone survey conducted
between November 2003 and February 2004. In each of the four months, eligible samples were randomly
assigned to one of three experimental conditions: advance letter without an incentive, advance letter plus
$5 incentive and advance letter plus $10 incentive. The same follow-up procedures, including promised
refusal conversion payments are used in all three groups. The measure for response quality in such studies
are inevitably subjective; they can be binary (e.g., “mostly compete” vs “partially complete,” or whether
a particularly important question is answered) or continuous (e.g. percent of missing items). As we don’t
have access to this data set, below we only discuss the validity of our assumptions.
The SUTVA is reasonable as these are random digit dial samples from the coterminous United States.
The monotonicity assumption is also plausible. As argued by survey sampling experts, incentives will
motivate response as they compensate for the relative absence of factors that might otherwise stimulate
cooperation (Singer and Kulka, 2002), so that individuals who would respond with a lower incentive would
also respond if offered a higher incentive. Empirical evidence in this study also supports this assumption:
the response rates for the three experimental groups were 51.7%, 63.8% and 67.7% (Curtin et al., 2007).
7 Discussion
In randomized trials with truncation by death, the average causal effects in basic principal strata are often of
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interest as they provide causally meaningful and interpretable summaries of the treatment effects. However,
for trials with multiple treatment arms, there are usually many such causal contrasts that are of interest to
investigators. In this article, we consider testing and estimation problems on the basic principal stratum
causal effects. Specifically, we propose three scientific questions to understand the overall treatment effect
and individual principal stratum causal effects. We then develop novel inference procedures to answer these
questions, and show that the proposed procedures have desirable asymptotic properties.
Compared to analyzing a multiarm trial in a standard setting, the main difficulty introduced by truncation
by death is that the causal estimands are not identifiable. In this case, we show that compared to marginal
methods, the (ANOVA type) simultaneous inference methods provide more power for testing the overall
treatment effect, and the advantage remains even with an infinite sample size. These results demonstrate
the importance of addressing both joint and marginal hypotheses in a causal analysis of multiarm trials
with truncation by death. This idea may be applied to analyse multiarm trials in other settings in which
the causal estimands are not identifiable. For example, in multiarm trials with non-compliance, existing
methods consider the causal contrasts separately (Cheng and Small, 2006; Long et al., 2010). Although
results obtained with such methods are valid, they are often not informative, especially in the case where
there are more than three treatment arms (Long et al., 2010). In this case, a simultaneous inference method
may yield a greater posterior probability of claiming an overall treatment effect and the joint posterior
credible intervals are less likely to contain the origin.
In analyzing a multiarm trial with truncation by death, researchers may dichotomize the treatment vari-
able to simplify an analysis, especially in settings where the multiarm trials consist of a placebo arm and
several dosage groups for an active treatment. One such example is the HVTN 503 study, where the treat-
ment groups 1 and 2 can be considered as different versions of the experimental vaccine. However, as noted
by Hernán and VanderWeele (2011), results from analyses that combine treatment arms in this way may not
be generalizable to other population as the causal effect of a compound treatment depends on the distribution
of treatment versions in the target population. Moreover, because of the non-identifiability of SACEs, one
may fail to find an overall treatment effect that could have been found by applying the proposed simultane-
ous inference procedure. For example, for the HVTN 503 study, if one were to collapse the active treatment
groups into a single compound treatment, then the 95% credible intervals for the SACE corresponding to
this compound treatment would be [0.000, 0.253], with which one could not claim any clinically relevant
treatment effect.
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To account for sampling uncertainty in the observed data distribution, we use Bayesian analysis methods
to obtain posterior samples of identifiable quantities p. An alternative Bayesian procedure to our method
involves posterior sampling on the mean potential outcomesµm−1. This alternative approach would directly
yield the posterior rejection rate ofH0 and credible intervals for ∆max,slb without resorting to techniques we
have introduced. However, as µm−1 is not identifiable from the observed data, it turns out that the posterior
estimates of ∆max are extremely sensitive to the prior specification on µm−1. We refer interested readers to
Richardson et al. (2011) for a further discussion of this issue.
The problem we consider here is similar to an instrumental variable analysis in that both problems can
be analysed under the principal stratification framework. When the exposure variable in an instrumental
variable analysis is binary, the exclusion restriction assumption is closely related to the null hypothesis in
the truncation by death problem, namely the causal effect in the always-survivor group is zero. Hence the ap-
proach we develop here may be used to partially test the exclusion restriction assumption of an instrumental
variable model.
There are several possible extensions to our framework. For example, we have restricted our attention to
binary outcomes in this article. We are currently exploring extensions to deal with continuous and categor-
ical outcomes. In addition, covariate information may be employed to sharpen bounds on SACEs. Another
possible extension is to introduce sensitivity parameters for better understanding of the causal effects of
interest. The tests and bounds we have developed here correspond to extreme results of corresponding
sensitivity analyses.
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1 Algorithm for identifying ∆max,slb
See Algorithm S1.
Algorithm S1 An algorithm for identifying ∆max,slb
1. Solve the following linear programming problem:
minimize α subject to: ∑
g∈Ωz
pzgµ
z
g = m(z), z = 0, . . . ,m− 1;
max (0,m(z)− pzDmL) ≤
∑
g∈Ωm−1
pzgµ
z
g ≤ min (1− pzDmL,m(z)) , z = m;
µz1g − µz2g ≤ α, ∀g, z1 ≥ z2;
0 ≤ µzg ≤ 1, ∀g, z
2. Report the value of the linear programming problem above as ∆max,slb
2 Simulation studies
We now use a hypothetical example to illustrate the advantage of the simultaneous inference procedures
proposed in Section 3 and 4 in the main text for testing the overall treatment effect. Let the comparison
method be the approach that considers each ∆(z1, z2; g) separately, and it accepts or rejects the null based on
the marginal feasible regions of ∆(z1, z2; g). With the comparison marginal testing method, one rejects the
hypothesisH0 only if at least one of the marginal feasible regions excludes 0. In other words, the comparison
method rejects H0 if the observed data not only provide evidence for existence of a non-zero treatment
effect, but also contain information on the specific principal strata and treatment arms that correspond to
this treatment effect. As explained in Remark 3 in the main text, this generally yields a smaller posterior
rejection probability. In addition, with the comparison method, one estimates the lower bound on ∆max
1
Table S1: Observed data counts in a hypothetical example.
Observed subgroup Counts
Y = 1, S = 1, Z = 0 n1
Y = 0, S = 1, Z = 0 40− n1
S = 0, Z = 0 360
Y = 1, S = 1, Z = 1 56
Y = 0, S = 1, Z = 1 24
S = 0, Z = 1 320
Y = 1, S = 1, Z = 2 108
Y = 0, S = 1, Z = 2 12
S = 0, Z = 2 280
to be the maximal sharp lower bound for all ∆(z1, z2; g) that appear in equation (1) in the main text. We
denote this lower bound as ∆max,mlb, where “mlb” is short for “marginal lower bound.” One can see from
the numerical example in Remark 3 in the main text that ∆max,mlb is in general no larger than ∆max. This
is because the comparison marginal estimation method does not use information on the dependence among
feasible regions of causal contrasts ∆(z1, z2; g). In the simulation studies, we empirically evaluate the
difference between the proposed simultaneous inference methods and the comparison marginal inference
methods for testing the overall treatment effect.
Suppose that we have a three-arm vaccine trial with two vaccine groups and one placebo group, and
there are 400 subjects in each group. The hypothetical data example is listed in Table S1, where n1 is a
parameter taking integer values between 0 and 40. The conditional frequencies m(0), m(1) and m(2) in
this example are 0.025n1, 0.7 and 0.9, respectively. In our example, there are 10% of the study sample in
each of the principal strata LLL,DLL,DDL, while the rest belongs to the DDD stratum.
Results in Figure S1 show that for some values of n1, the simultaneous and marginal methods compared
here yielded similar results. However, in some other cases, the results could be very different. For example,
when n1 = 36, the simultaneous testing method estimated the posterior probability of rejecting H0 to be
98.8%, compared to an estimate of 4.0% from the marginal testing method. When n1 = 20, the simultaneous
estimation method estimated the 95% credible interval for ∆max,slb to be [0.029, 0.404], based on which
one was able to claim a clinically relevant treatment effect at margin ∆0 = 0.02. The marginal estimation
method, however, estimated the 95% credible interval for ∆max,mlb to be [4× 10−4, 0.363], with which one
failed to claim a clinically relevant treatment effect at the same margin.
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Figure S1: Results from analyzing the hypothetical data set in Table S1. The left panel shows the posterior
probability of rejecting H0 using the proposed simultaneous testing method and the comparison marginal
testing method. The right panel shows the posterior mean (solid lines) and 95% credible intervals (dashed
lines) for lower bounds on ∆max, the maximal treatment effect among all possible basic principal strata
and treatment comparisons. The red curves correspond to sharp lower bounds obtained using the proposed
simultaneous estimation method, and the black curves correspond to lower bounds obtained using the com-
parison marginal estimation method. The blue horizontal line corresponds to a clinically meaningful margin
of 0.02.
3 Data Table for the HVTN 503 study
Table S2 gives the observed data counts for the HVTN 503 trial.
4 Proofs of theorems and lemmas
A Proof of Theorem 1
The proof for the general multi-arm case is very similar to the discussion for the three-arm case. The only
non-trivial generalization is for Step 3 of Algorithm 1 in the main text. Instead of checking the pairwise
intersections of (Bkz; z = k, . . . ,m), we check their joint intersection. This relies on the observation that
if we let g = DkLm+1−k, then ωkg = 1 and the feasible region for Bkk is a one point set {
∫
ydQkg}.
Consequently,
∩
z=k,...,m
Bkz 6= ∅ (S1)
implies that
Bkz1 ∩Bkz2 6= ∅,∀z1 > z2 ≥ k. (S2)
3
Table S2: Observed data counts in the HVTN 503 trial. Z denotes the treatment arm, S denotes the infection
status, and Y is the dichotomized outcome of CD4 count. Y = ∗ denotes that Y is missing.
Observed subgroup median CD4 > 350 cells/mm3 median CD4 > 200 cells/mm3
Y = 1, S = 1, Z = 0 19 29
Y = 0, S = 1, Z = 0 14 4
Y = ∗, S = 1, Z = 0 4 4
S = 0, Z = 0 363 363
Y = 1, S = 1, Z = 1 12 16
Y = 0, S = 1, Z = 1 4 0
Y = ∗, S = 1, Z = 1 2 2
S = 0, Z = 1 94 94
Y = 1, S = 1, Z = 2 34 44
Y = 0, S = 1, Z = 2 10 0
Y = ∗, S = 1, Z = 2 1 1
S = 0, Z = 2 243 243
Note there are only m− k pairs of comparisons involved in (S1), compared to (m+ 1− k)(m− k)/2 pairs
of comparisons in (S2).
B Proof of Theorem 2
To prove Theorem 2, we note that the assumptions of Theorem 2 and the observed data distribution impose
the following constraints on µzg:
Qz =
∑
g∈Ωl−1
pzgQ
z
g + p
z
gQ
z
g +
∑
g¯∈Ωz\Ωl
pzg¯Q
z
g¯, (S3)
µ
M(g)
g = · · · = µmg .∀g ∈ Ωl−1, (S4)
where Qz denotes the distribution of outcome Y in treatment arm z. To simplify (S3) and (S4), we use
the following lemmas, which say that both the proportions of basic principal strata pzg and the means of
Bernoulli distributions (Qzg, g ∈ Ωl−1, z ≥ M(g)) are identifiable. Proofs of these lemmas are left to the
end of this subsection.
Lemma 2: The proportions of basic principal strata, namely (pzg; g ∈ Ωm−1, z ≥ M(g)) are identifiable
from the observed data.
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Lemma 3: Suppose that (6) in the main text holds for all k < l, then (µzg; g ∈ Ωl−1, z ≥ M(g)) are
identifiable from the observed data.
As the Bernoulli distribution Qzg is uniquely determined by its mean µ
z
g, the constraints on µ
z
g can be
simplified as
Qzg = ω
z
gQ
z
g +
∑
g¯∈Ωz\Ωl
ωzg¯Q
z
g¯, (S5)
where Qzg a Bernoulli distribution with mean mg(z). Applying Imai (2008)’s results to (S5), we have
Blz =
[∫
ydLωzg (Q
z
g),
∫
ydUωzg (Q
z
g)
]
.
This completes the proof of Theorem 2.
Proof of Lemma 2
Proof. Let pizg = P (G = g|Z = z). Following Assumption 2, pizg is independent of treatment arm z and
hence can be written as pig. Under Assumption 3, we have the following equations:
P (S = 1|Z = 0) = piLm+1 ,
P (S = 1|Z = 1) = piLm+1 + piDLm ,
· · ·
P (S = 1|Z = z) = piLm+1 + . . .+ piDzLm+1−z , (S6)
· · ·
P (S = 1|Z = m) = piLm+1 + . . .+ piDmL,
1 = piLm+1 + . . .+ piDm+1 .
It can be shown that there exists an unique solution to equation (S6) and hence (pig, g ∈ Ωm) are identifiable
from equation (S6). It then follows that (pzg; g ∈ Ωm−1, z ≥M(g)) are also identifiable.
Proof of Lemma 3
Proof. As (6) in the main text holds for all k < l, we only need to show that µ
M(g)
g is identifiable from the
observed data. We show this by applying the induction method onM(g).
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Base case: if M(g) = 0, then µM(g)g = µ0Lm+1 = P (Y = 1|Z = 0, S = 1) by the monotonicity
assumption (Assumption 3).
Inductive step: suppose that µ
M(g)
g is identifiable from the observed data for all principle strata g such
thatM(g) ≤ k. Following the monotonicity assumption (Assumption 3), we have the following identify:
P (Y = 1|Z = k + 1, S = 1) =
∑
g∈Ωk
pkgµ
k
g + p
k+1
Dk+1Lm−kµ
k+1
Dk+1Lm−k
=
∑
g∈Ωk
pkgµ
M(g)
g + p
k+1
Dk+1Lm−kµ
k+1
Dk+1Lm−k , (S7)
where the last step in (S7) follows from the working hypotheses.
Following Lemma 2, (pkg ; g ∈ Ωk) and pk+1Dk+1Lm−k are identifiable from the observed data. Following
the induction hypotheses, (µM(g)g ; g ∈ Ωk) are also identifiable. Consequently, µk+1Dk+1Lm−k is identifiable
from (S7). In other words, for principle strata g such thatM(g) = k + 1, µM(g)g is also identifiable from
the observed data.
By the induction principle, we have finished our proof.
C Proof of Theorem 4
Theorem 4 is a direct consequence of the following lemma:
Lemma 4: Let h be a mixture of k Bernoulli distributions f1, . . . , fk: h =
k∑
j=1
αjfj , where the mixing
proportions αj , j = 1, . . . , k are known. Let P, P1, . . . , Pk be the probability of a positive outcome under
h, f1, . . . , fk respectively, then
max
0, P − k∑
j=l+1
αj
 ≤ l∑
j=1
αjPj ≤ min
 l∑
j=1
αj , P
 .
Lemma 4 is a generalization of Lemma 1 in Cheng and Small (2006) and can be proved by solving the
linear programming problem of minimizing or maximizing
l∑
j=1
αjfj subject to constraints P =
k∑
j=1
αjPj .
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